UPC grants ‘in absentia’ permanent injunction on agricultural tool

​
July 21, 2025

Maschio Gaspardo S.p.A. v Spiridonakis Bros GP (UPC_CFI_513/2024 relating to EP1998604)

Order of 25 June 2025 (ORD_17812/2025 [1])

This Decision from the Central Division of the Unified Patent Court in Milan relates to EP1998604 (EP ‘604). The Applicant, Maschio Gaspardo S.p.A. ("MG"), requested a permanent injunction by Article 63(1) UPCA against Spiridonakis Bros GP ("Spiridonakis"), to prevent the sale and distribution of Spiridonakis' ‘Bellota tool'.

Spiridonakis did not file an infringement defence, and the Court granted the requested permanent injunction, ordering Spiridonakis to refrain from any further acts of infringement, to provide MG with any information regarding the origin and the distribution channels of the infringing products, and to bear the legal costs of the proceedings and other expenses incurred by MG.

Decision ‘in absentia'

MG filed an action for patent infringement against Spiridonakis on 5 September 2024 with the Central Divisionin Milan. The alleged infringement relates to the sale and distribution of an agricultural tool by the Defendant under the name of ‘Bellota tool'. The ‘Bellota tool' allegedly infringed EP1998604, validated in France, Turkey, Italy, Germany, Romania, Czech Republic and Bulgaria.

MG requested a decision by default under R. 355(1) RoP, based on Spiridonakis failing to file written submissions within the relevant time limit and failing to appear at the oral hearing. MG requested grant of a permanent injunction by Article 63(1) UPC in the contracting member states where EP ‘604 is valid.

The Court stated that a default decision against a Defendant is subject to:

  • verification of proper service;
  • the absence of preliminary grounds for inadmissibility of the claim; and
  • the assessment that the facts put forward by the claimant justify the remedy sought (Rule 355.2).

The Court stated that it was apparent from the service notification that the statement of claim was validly served on Spiridonakis on January 2, 2025.

The Court also stated that Rule 355.2 imposes de minimis factual allegations for a decision to be issued in absentia, namely those set out in Rules 12 and 13 RoP. That is, reasonably providing the Court with the patent documentation, as well as all documents and evidence related to infringement and damages, if requested.

Furthermore, the Court found that bringing the action before the Central Division was justified since:

  • the principal place of residence and place of business of Spiridonakis is Greece, which is outside the territory of the Contracting Member States (Article 33(1) UPCA, paragraph 3); and
  • Bulgaria, as a UPCA Contracting member state, does not host a local division and does not participate in a regional division (Article 33(1) UPCA, paragraph 4). Bulgaria was the place where the specific infringing acts were alleged to have occurred.

Validity

The Court did not find it was necessary to take a stand on patent invalidity, since this is not an issue that is raised by the Court ex officio, even in the case of a decision by default. According to the case law of the European Court of Justice (Case C-44/21), granted European patents enjoy a presumption of validity from the date of publication of their grant (cf. LD Munich, UPC_CFI_508/2023, 9 January 2025, air up v Guangzhou Aiyun).

Accordingly, EP ‘604 was presumed to be valid by the Court.

Infringement

EP ‘604 relates to a ‘reversible tool for agricultural subsoilers'. This is a tool that can be mounted on agricultural machinery to penetrate and break up compacted soil layers below the surface.

MG conducted two online purchases (on 19 July 2024 and 6 August 2024) through Spiridonakis' website for delivery of the allegedly infringing ‘Bellota tool' in Bulgaria. These products were labelled in the shipment receipts as "Spare parts nail riper nail Maschio" and "Spare parts for agricultural machinery", according to automatic translations to English.

MG's CTO inspected the accused products and submitted (together with photographic evidence) that they were almost identical in shape, dimensions, and features to the patented embodiment. A panel of judges of the Milan Central Division travelled to Cremona to visually assess the structure and operation of the original product sold by MG and the allegedly infringing product sold by Spiridonakis.

Moreover, it was noted by MG that the ‘Bellota tool' on the website of Spiridonakis.com was marketed as a "Point Riper Maschio Bellota" tool, thereby evoking the name of the patent owner, Maschio Gaspardo, with the purpose of confusing the customer about the origin of the product. It was also submitted that the ‘Bellota tool' also showed the product code R17622960, which is the distinguishing code of MG's product.

MG stated that Spiridonakis is offering and placing on the market products having all the features of at least claims 1, 2, 3, 5, 6, 9, and 10 of patent EP ‘604, at least in Bulgaria, where EP ‘604 is valid. The Court decided that the statement of claim was sufficiently detailed and supported by consistent evidence, in line with the requirements of Rule 355.2.

The Court decided that that the infringing offer, sale and distribution of the ‘Bellota tool' in Bulgaria was proven. While the Court primarily saw this as an act of primary infringement (Art. 25 UPCA), in the alternative the Court held that the requirements for indirect infringement (Art. 26 UPCA) with regard to double territoriality were met, since the attacked embodiment could be supplied at least in Bulgaria, where EP ‘604 is valid, and the ‘Bellota tool' is shipped.

Order to Communicate Information

It was further submitted that that the allegedly infringing product bears the trademark of the company Bellota, suggesting that Spiridonakis' allegedly infringing product is manufactured by the company Bellota. MG stated that they have a legitimate interest in understanding where the production takes place and who might be the infringing company, therefore justifying requesting the Court to order Spiridonakis to communicate, by Article 67(1) UPCA, information concerning the origin and distribution channels of the infringing products.

Decision

The Court found that the request from MG of ordering Spiridonakis to bear the legal costs of € 25,000 was well-founded under RoP 152, considering that the costs requested (€ 15,000 euro for the preparation of the case and € 10,000 euro for the oral hearing) were well below the minimum level of recoverable costs set out by the Presidium for an infringement action and appeared to be in line with the activity done by the legal representatives.

Accordingly, the Court granted the permanent injunction and ordered Spiridonakis refrain from any acts of infringement within UPC member states, and the payment of € 25,000 for legal costs and to refund the court fees paid by MG.

The Court also ordered Spiridonakis to communicate to MG information regarding the origin and the distribution channels of the infringing products, the quantities produced, delivered, ordered, the price related to the sales and the identity of any person involved in the production of the ‘Bellota tool'.

[1] https://www.unified-patent-court.org/en/node/136198

The Latest Thought Leadership pieces in the Content Hub

Applying Ocado, the UPC grants a R262 request to access CFI documents
July 9, 2025
NJOY Netherlands B.V v Juul Labs International, Inc (UPC_CFI_309/2023) Order issued 9 June 2025 (ORD_27305/2025) [1] The Paris Central Division revoked Juul Lab's patent EP 3 498 115 B1 by decision...
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​